/
Other
Fasting Conditions
36
Pipeline Programs↗
11
Active Trials↗
48
Companies Involved↗
Fasting Conditions is a moderately active landscape with 36 programs across 48 companies. The most active players are Daewoong Pharmaceutical Co. LTD., Berlin-Chemie AG Menarini Group, Boryung Pharmaceutical Co., Ltd. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 111
Phase 2
No programs
Phase 31
Approved
No programs
Analysis
Trial Status
507
clinical trials
Completed460 · 91%
Unknown status27 · 5%
Withdrawn7 · 1%
Not yet recruiting5 · 1%
Recruiting4 · 1%
Active, not recruiting2 · 0%
Other2 · 0%
Clinical Trials
Trial Activity
507 trials
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
Active, not recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06326671·39 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06326671·39 enrolledA Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06487416·186 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06487416·186 enrolled
Page 1 of 34
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)